Ross Moat Sells 2,367 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 2,367 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $48.58, for a total transaction of $114,988.86. Following the sale, the chief operating officer owned 12,029 shares of the company’s stock, valued at approximately $584,368.82. The trade was a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 0.6%

NASDAQ KNSA opened at $47.33 on Friday. The company has a 50-day simple moving average of $45.89 and a two-hundred day simple moving average of $42.20. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.29 and a 12-month high of $50.03. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of 63.96 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. During the same quarter in the previous year, the company earned ($0.12) earnings per share. The business’s quarterly revenue was up 65.0% on a year-over-year basis. Equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals International

Institutional investors have recently modified their holdings of the company. USA Financial Formulas purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth about $32,000. Smartleaf Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth about $36,000. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth about $41,000. Finally, CIBC Private Wealth Group LLC bought a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth about $41,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KNSA has been the subject of several analyst reports. Wedbush upped their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target for the company. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $55.29.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.